Logo
x

Search category

Subscribe Now

avß6 Integrin

AbbVie Exercises its Option to License Morphosys' αvβ6 Integrin Inhibitor Program for Fibrotic Disease

AbbVie Exercises its Option to License Morphosys' αvβ6 Integrin Inhibitor Program for Fibrotic Disease

  • August 25, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.